Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:BMRN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$202.00+0.5%$199.92$118.03▼$216.45$12.40B0.41472,097 shs369,067 shsBMRNBioMarin Pharmaceutical$54.48-0.1%$55.29$51.56▼$73.51$10.46B0.332.16 million shs2.10 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+0.49%-4.04%+4.51%+20.62%+58.20%BMRNBioMarin Pharmaceutical-0.13%+2.23%+1.32%-7.68%-22.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$202.00+0.5%$199.92$118.03▼$216.45$12.40B0.41472,097 shs369,067 shsBMRNBioMarin Pharmaceutical$54.48-0.1%$55.29$51.56▼$73.51$10.46B0.332.16 million shs2.10 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+0.49%-4.04%+4.51%+20.62%+58.20%BMRNBioMarin Pharmaceutical-0.13%+2.23%+1.32%-7.68%-22.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 2.94Moderate Buy$249.8023.66% UpsideBMRNBioMarin Pharmaceutical 2.55Moderate Buy$93.2671.19% UpsideCurrent Analyst Ratings BreakdownLatest ASND and BMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025ASNDAscendis Pharma A/SWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025BMRNBioMarin PharmaceuticalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/17/2025ASNDAscendis Pharma A/SRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$271.0010/16/2025ASNDAscendis Pharma A/SRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/13/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$203.00 ➝ $254.0010/9/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$260.00 ➝ $264.0010/9/2025BMRNBioMarin PharmaceuticalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$116.00 ➝ $119.0010/8/2025ASNDAscendis Pharma A/SWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025BMRNBioMarin PharmaceuticalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025ASNDAscendis Pharma A/SWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025BMRNBioMarin PharmaceuticalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$490.75M25.39N/AN/A($1.88) per share-107.45BMRNBioMarin Pharmaceutical$3.06B3.41$3.24 per share16.81$29.69 per share1.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$5.16N/A841.67N/A-54.94%N/A-24.31%11/13/2025 (Estimated)BMRNBioMarin Pharmaceutical$426.86M$3.3716.1712.500.6821.45%12.59%10.13%10/27/2025 (Estimated)Latest ASND and BMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025ASNDAscendis Pharma A/S-$0.49N/AN/AN/AN/AN/A10/27/2025Q3 2025BMRNBioMarin Pharmaceutical$0.89N/AN/AN/A$782.42 millionN/A8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ABMRNBioMarin PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.020.69BMRNBioMarin Pharmaceutical0.105.563.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ABMRNBioMarin Pharmaceutical98.71%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%BMRNBioMarin Pharmaceutical0.85%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01761.70 million37.02 millionOptionableBMRNBioMarin Pharmaceutical3,040192.02 million190.38 millionOptionableASND and BMRN HeadlinesRecent News About These CompaniesAlphaQuest LLC Increases Position in BioMarin Pharmaceutical Inc. $BMRNOctober 25 at 9:56 AM | marketbeat.comWhat to Expect from Biomarin Pharmaceutical's EarningsOctober 24 at 12:27 PM | benzinga.comSector Gamma AS Decreases Position in BioMarin Pharmaceutical Inc. $BMRNOctober 24 at 8:58 AM | marketbeat.comBioMarin Pharmaceutical (BMRN) Projected to Post Quarterly Earnings on MondayOctober 24 at 8:14 AM | marketbeat.com3 of Wall Street’s Favorite Stocks to Target This WeekOctober 24 at 7:26 AM | finance.yahoo.comChicago Partners Investment Group LLC Purchases New Stake in BioMarin Pharmaceutical Inc. $BMRNOctober 24 at 4:43 AM | marketbeat.comStrategic Revenue Adjustments and Positive Outlook Drive Buy Rating for BioMarin PharmaceuticalOctober 23 at 7:51 AM | tipranks.comTD Asset Management Inc Sells 17,881 Shares of BioMarin Pharmaceutical Inc. $BMRNOctober 23 at 4:19 AM | marketbeat.comBioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ETOctober 22 at 4:05 PM | prnewswire.com4,989 Shares in BioMarin Pharmaceutical Inc. $BMRN Bought by Jackson Thornton Wealth Management LLCOctober 21, 2025 | marketbeat.comBioMarin Pharmaceutical Inc. $BMRN Stock Holdings Decreased by Vanguard Personalized Indexing Management LLCOctober 21, 2025 | marketbeat.comVIRGINIA RETIREMENT SYSTEMS ET Al Makes New $19.71 Million Investment in BioMarin Pharmaceutical Inc. $BMRNOctober 20, 2025 | marketbeat.comApplied Finance Capital Management LLC Makes New $265,000 Investment in BioMarin Pharmaceutical Inc. $BMRNOctober 19, 2025 | marketbeat.comCantor Fitzgerald Brokers Boost Earnings Estimates for BMRNOctober 18, 2025 | americanbankingnews.comCantor Fitzgerald Reiterates a Buy Rating for BioMarin Pharmaceutical (BMRN)October 17, 2025 | finance.yahoo.comWCM Investment Management LLC Has $513,000 Stock Holdings in BioMarin Pharmaceutical Inc. $BMRNOctober 17, 2025 | marketbeat.comNorthRock Partners LLC Acquires New Stake in BioMarin Pharmaceutical Inc. $BMRNOctober 17, 2025 | marketbeat.comCwm LLC Purchases 27,894 Shares of BioMarin Pharmaceutical Inc. $BMRNOctober 17, 2025 | marketbeat.comBMRN FY2025 EPS Forecast Raised by Cantor FitzgeraldOctober 16, 2025 | marketbeat.comAware Super Pty Ltd as trustee of Aware Super Buys New Shares in BioMarin Pharmaceutical Inc. $BMRNOctober 16, 2025 | marketbeat.comA Look at BioMarin Pharmaceutical’s Valuation as Revenue Growth and Pipeline Optimism Drive Investor FocusOctober 16, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASND and BMRN Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$202.00 +0.99 (+0.49%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$202.50 +0.50 (+0.25%) As of 10/24/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.BioMarin Pharmaceutical NASDAQ:BMRN$54.48 -0.07 (-0.13%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$54.74 +0.26 (+0.48%) As of 10/24/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
